DEFM14A: Enzo Biochem Shareholders to Vote on $0.70 Cash Acquisition by Battery Ventures Affiliate

Enzo Biochem, Inc. shareholders are set to vote on a definitive merger agreement to be acquired by Bethpage Parent, Inc., an affiliate of Battery Ventures, for $0.70 per share in cash, representing a significant premium over recent trading prices.

Summary

• Enzo Biochem, Inc. (the Company) has entered into a definitive Agreement and Plan of Merger with Bethpage Parent, Inc. (Parent), an affiliate of Battery Ventures, and Bethpage Merger Sub, Inc., for an all-cash acquisition.
• Under the terms of the Merger Agreement, shareholders will receive $0.70 in cash for each share of common stock they own, subject to applicable withholding taxes.
• This per share price represents a premium of approximately 32% over the Company's closing stock price on June 23, 2025, and approximately 23% over the volume-weighted average price for the 30-day period ending June 23, 2025.
• The Board of Directors, acting upon the recommendation of a special committee of independent directors, unanimously determined the merger to be in the best interests of the Company and its shareholders and recommends voting FOR the Merger Proposal.
• A Special Meeting of Shareholders will be held virtually on August 19, 2025, at 10:00 a.m. EDT, for shareholders to vote on the Merger Proposal and an Adjournment Proposal.
• The merger requires the affirmative vote of a majority of the Company's outstanding shares of common stock entitled to vote.
• Officers, directors, and significant shareholders (Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP), collectively holding approximately 23% of outstanding shares, have entered into Support Agreements to vote in favor of the merger.
• If the merger is completed, the Company's common stock will be delisted from OTCQX and deregistered under the Securities Exchange Act of 1934, ceasing to be a publicly traded company.
• Company options with an exercise price greater than $0.70 per share will be cancelled for no consideration, while vested restricted stock units (including all held by Board members) will be converted into cash at the $0.70 per share price.
• Outstanding Company Warrants will be cancelled in exchange for their Black-Scholes Value, as per Warrant Cancellation Agreements executed prior to the merger agreement.

Sentiment

Score: 7

Explanation: The sentiment is positive for shareholders due to the significant premium offered and the certainty of cash value, especially given the Company's stated financial challenges and risks as a standalone entity. The Board's unanimous recommendation and the support agreements from major shareholders reinforce this positive outlook for the transaction's completion.

Positives

• The merger offers immediate liquidity and certainty of value to shareholders, eliminating long-term business and execution risks associated with operating as a standalone company.
• The $0.70 per share cash consideration represents a compelling premium of approximately 32% over the closing price on June 23, 2025, and 75% over the closing price on April 22, 2025 (following the strategic review announcement).
• The Board of Directors, after a comprehensive six-month review of strategic alternatives, unanimously determined that the merger represents the best alternative available to the Company and its shareholders.
• The transaction has a high degree of certainty of closing due to specific and limited conditions, including no approval required from Parent's shareholders, and the commitment of Parent and the Company to use reasonable best efforts to consummate the merger.
• The financing for the merger, up to $30,000,000, is committed via an Equity Commitment Letter from Battery Ventures affiliates, and its availability is not a condition to closing.

Negatives

• Shareholders will no longer participate in any future earnings or growth of the Company, nor will they benefit from any potential future appreciation in the Company's value.
• The Company's internal projections indicate cumulative operating losses of over $23 million for fiscal years 2025-2030, with negative EBITDA until 2029 and negative unlevered, after-tax free cash flow until 2030 if it remains a standalone entity.
• The Company faces a difficult operating, political, and regulatory environment for life sciences companies, including potential impacts from tariffs, reduced federal spending, and cuts to federal agencies that fund research and development.
• Significant contingent liabilities from ongoing litigation could require the Company to use a majority of its currently available cash, potentially having a material adverse effect on its financial condition if the merger is not completed.
• There is uncertainty regarding the Company's necessary liquidity to continue operations if the merger or an alternative strategic transaction is not completed.
• The Company is subject to restrictions on its business conduct prior to the merger's consummation, which may delay or prevent it from pursuing new business opportunities.
• The Company may be required to pay a termination fee of $2,500,000 and/or an expense reimbursement of up to $1,000,000 to Parent if the merger agreement is terminated under certain circumstances.

Risks

• The Company would cease to exist as an independent, publicly traded entity, and shareholders would lose participation in future earnings or growth.
• If the Company remained a standalone entity, its projections indicate years of continued operating losses and negative cash flow.
• The operating, political, and regulatory environment for life sciences companies is becoming increasingly difficult, including the imposition of tariffs, reduced federal spending, and potential cuts to federal agencies funding research and development.
• The Company is a party to significant litigations, which, if determined adversely, could require the use of a majority of its currently available cash and materially adversely affect its financial condition.
• Management is uncertain about the Company's liquidity for continued operations if the merger or an alternative strategic transaction is not completed.
• Restrictions on the Company's business conduct prior to the merger's consummation may prevent it from undertaking new business opportunities.
• The Company may incur significant costs related to the merger, many of which are payable regardless of whether the merger is consummated, potentially disrupting business operations and negatively affecting financial results.
• There is a risk that the merger might not be completed, which could lead to a significant decline in the Company's share price.
• The merger carries a risk of litigation.
• Regulatory approvals could be required after the filing date, and there is a risk that such approvals may not be obtained.
• There is a risk of losing key management or other personnel during the pendency of the merger.
• The Company's officers and directors have interests in the merger that may differ from those of general shareholders.

Future Outlook

The Company's management projections, prepared on a standalone basis, forecast cumulative operating losses exceeding $23 million through fiscal year 2030, with negative EBITDA until 2029 and negative unlevered, after-tax free cash flow until 2030. The Board believes the merger provides immediate liquidity and certainty of value, mitigating the risks and uncertainties of continuing as a standalone company, including a challenging regulatory environment and significant contingent liabilities.

Management Comments

• The Board of Directors, after considering various factors and upon the recommendation of a special committee, unanimously determined that the entry into the Merger Agreement is in the best interests of the Company and its shareholders, and advisable.
• The Board approved the execution, delivery, and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated by the Merger Agreement, including the Merger.
• The Board recommended that the Company's shareholders approve the Merger Agreement and directed that it be submitted for consideration at the Special Meeting for their approval.
• Kara Cannon, Chief Executive Officer, encouraged shareholders to read the entire proxy statement carefully and vote as soon as possible, emphasizing the importance of their vote for the merger's completion.

Industry Context

The filing highlights a challenging macroenvironment affecting the life sciences market, including foreign trade policy, tariffs, and deep cuts to federal spending, which contribute to the Company's operational difficulties and negative cash flow. The acquisition by Battery Ventures, a technology-focused investment firm, suggests a private equity play to restructure or optimize the life sciences business outside of public market scrutiny, potentially leveraging specialized expertise to navigate industry headwinds and address the Company's specific liabilities.

Comparison to Industry Standards

• BroadOak's financial analysis included a 'Selected Public Companies Analysis' comparing Enzo Biochem to BICO Group AB, Cytek Biosciences, Inc., Harvard Biosciences, Inc., Maravai LifeSciences, Inc., and Standard BioTools Inc., all of equivalent revenue scale in the life science tools industry. Enzo's implied enterprise value from the $0.70 purchase price ($21.2M $34.2M) was lower than the implied enterprise value ranges derived from the selected public companies' LTM Revenue ($29.8M $36.7M) and FY2026 Revenue ($31.0M $40.9M) multiples, suggesting the offer is below public market valuations for comparable companies, but this is offset by Enzo's specific financial challenges.
• A 'Selected Precedent Transactions Analysis' reviewed eight transactions involving target companies with similar scale and focus on the life science tools market, including Akoya Biosciences/Quanterix, NanoString Technologies/Bruker Corporation, and IBEX Technologies/BBI Group. Enzo's implied enterprise value from the $0.70 purchase price ($21.2M $34.2M) was significantly lower than the implied enterprise value ranges derived from the selected precedent transactions' LTM revenue ($52.2M $62.4M) and FY2026 Revenue ($51.1M $61.0M) multiples, indicating the offer is below typical acquisition multiples in the industry, likely reflecting Enzo's specific operational and litigation risks.
• A 'Premiums Paid Analysis' using median premiums from selected transactions (29.5% for one-day, 26.1% for one-week, 30.7% for one-month) indicated implied prices per share of $0.70, $0.68, and $0.71 respectively, aligning the $0.70 offer with typical premiums paid in comparable transactions, despite the lower absolute valuation multiples.
• The Discounted Cash Flow (DCF) analysis, based on management's forecasts of negative EBITDA until 2029 and negative unlevered free cash flow until 2030, resulted in implied enterprise value ranges of $16.8M $25.2M (Revenue Exit Multiple) and $4.2M $6.3M (EBITDA Exit Multiple), which are lower than the $0.70 per share implied enterprise value, suggesting the offer provides value above the Company's standalone projected financial performance.

Management Changes

Corporate Governance

Legal Proceedings

• The Company was involved in a class-wide settlement agreement in the class action data breach litigation, 'In re Enzo Biochem Data Breach Litigation, No. 2:23-cv-04282 (EDNY)', for $7.5 million, which has been paid.
• The Company is a party to a number of other litigations which, if determined adversely, would require the Company to use a majority of its currently available cash and would likely have a material adverse effect on its financial condition.
• The Company has agreed to keep Parent informed of shareholder litigation related to the merger and cooperate in its defense, not settling without Parent's prior written consent.

Related Party Transactions

• No new material related party transactions (as defined by Item 404 of Regulation S-K) have occurred since January 1, 2022, that have not been disclosed in SEC filings, other than ordinary course employment agreements and similar employee arrangements.

Stakeholder Impact

• Shareholders: Will receive a cash premium for their shares, providing immediate liquidity and certainty of value, but will no longer have an equity interest in the Company or participate in its future performance.
• Employees: Continuing employees will receive credit for prior service with the Company for purposes of vesting, eligibility, and benefit levels under Parent's employee benefit plans, and pre-existing condition exclusions will be waived for health benefits.
• Management/Directors: Vested Company RSUs will be converted to cash, while Company Options (all out-of-the-money) and unvested non-Board RSUs will be cancelled without consideration. Directors and officers will retain indemnification and insurance coverage for six years post-merger.
• Creditors: The merger is expected to be fully funded, including payment of aggregate merger consideration and transaction expenses, which should ensure obligations are met.
• Customers and Suppliers: The filing indicates an effort to preserve existing business relationships, suggesting minimal immediate disruption to these stakeholders.

Next Steps

• The Company will hold a Special Meeting of Shareholders on August 19, 2025, to vote on the Merger Proposal and the Adjournment Proposal.
• If approved, the merger is anticipated to be completed in the third quarter of calendar year 2025, assuming timely satisfaction of closing conditions.
• Following the merger, the Company's common stock will be delisted from OTCQX and deregistered under the Exchange Act.

Key Dates

Recommendation

The Board has unanimously recommended the merger, citing a compelling premium over recent trading prices and the elimination of significant risks associated with the Company's standalone operations, including projected long-term losses and substantial contingent liabilities. For a seasoned investor, the $0.70 cash offer provides a clear exit strategy at a favorable valuation relative to the Company's challenging financial outlook. Holding the stock until the merger closes allows investors to capture this premium with a high degree of certainty, given the committed financing and support agreements from major shareholders. A 'sell' recommendation would also be reasonable for those wishing to exit immediately and avoid any residual transaction risk, however small.

Keywords

Merger, Acquisition, Life Sciences, Biochem, Cash Offer, Shareholder Vote, Proxy Statement, Battery Ventures, ENZ, OTC Marketplace, Dissenters Rights, Equity Financing, Strategic Alternatives